Research and clinical trials

Handheld IUS could make noninvasive bowel assessment faster and more accessible for people with IBD, helping with triage and short-term monitoring without immediately resorting to endoscopy or advanced imaging.

If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.

A blood antibody (anti-integrin αvβ6) was associated with relapse risk in UC and may help predict who stays in long-term remission, which could affect monitoring and treatment planning.

People with IBD face higher osteoporosis risk; this study looked for a genetic variant (LCT-13910C>T) that might affect bone density but found no clear link in this cohort, so it does not change current bone-health...

Patients with Crohn's who develop intra-abdominal abscesses often face decisions about antibiotics, drainage, or surgery. Predictors like abscess size and imaging appearance may help estimate the chance of needing...

The paper identifies a new mechanism (VDAC1-driven mtDNA release activating cGAS–STING) that may drive inflammation in ulcerative colitis and a candidate compound (senkyunolide I) that blocks this pathway in preclinical...

The paper describes a new immunometabolic mechanism that strengthened intestinal barrier function and reduced colitis in mice, suggesting a potential pathway to develop therapies that boost ILC3-driven IL-22 production...

Sarcopenia or low muscle mass may be linked with worse endoscopic healing and reduced durability of biologic therapy in IBD, particularly Crohn's disease, which could matter for prognosis and treatment planning if...

The study investigates how specific gut bacterial strains can change colitis severity in experimental models — important because microbes are a focus of IBD research and potential therapies.

People with UC in remission who still have gut–brain interaction symptoms often look for safe ways to improve symptoms or gut microbiota balance.

Mirikizumab is being tested specifically in children with moderate-to-severe Crohn’s disease; successful results could expand treatment options for pediatric IBD. The study measures both symptom-based and endoscopic...

This trial is testing whether continued mirikizumab treatment helps children and teens with ulcerative colitis or Crohn’s disease achieve and maintain remission over the long term. Results could expand pediatric...

A structured ERP adapted for children could shorten hospital stays and improve recovery after pediatric GI surgery; this trial tested both clinical effectiveness and real-world implementation across many pediatric...

Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand...

People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.

Dietary strategies like the Mediterranean diet and time-restricted feeding could be low-risk ways to influence gut microbiota, short-chain fatty acids, and inflammation in people with ulcerative colitis; this trial will...

The study suggests a Moringa-derived polysaccharide may reduce inflammation in a mouse model of ulcerative colitis by altering gut microbiota, metabolites, and inflammatory/antioxidant signaling — a potential preclinical...

This review links lactic acid bacteria ecology in engineered communities to potential applications in gut health and IBD research, which could guide future microbiome-based interventions.

The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...

Preneoplastic (adenomatous and serrated) polyps can be precursors to colorectal cancer, so knowing how common they are and what raises risk may affect surveillance planning for people with ulcerative colitis.

If you had biologic treatment before bowel surgery, this study suggests restarting the same class of biologic after ileocolonic resection may prevent postoperative recurrence as well as switching to a new class — and may...

Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...

If you have PSC-IBD or care for someone who does, this study suggests the gut microbiota and its ability to make secondary bile acids may help drive inflammation and colorectal dysplasia risk.

Researchers are exploring natural compounds that may modulate gut microbes, barrier function, and immune signaling relevant to ulcerative colitis.

Intestinal fibrosis causes strictures and surgery in many people with Crohn's disease; new RNA-based antifibrotic strategies delivered by nanocarriers could offer non-surgical treatment options in the future if they can...

For people with ulcerative colitis who have already tried and failed one or more advanced therapies, this study suggests upadacitinib may lead to higher rates of steroid-free clinical remission and endoscopic healing...

This pooled analysis compares multiple microbiota-directed therapies and suggests FMT, probiotics, and synbiotics may improve clinical remission in adults with IBD, with FMT also showing benefit for endoscopic remission....

This study suggests a new, non‑live (“postbiotic”) approach—extracellular vesicles from pasteurized Akkermansia muciniphila—may reduce inflammation and improve barrier function in an experimental colitis model, which...

Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...

Better automated segmentation of inflammatory lesions could make colonoscopy assessments more objective and consistent, which matters for monitoring IBD activity and for clinical trials that rely on endoscopic endpoints.

Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...

Based on the title and source metadata, this appears to be a clinical study related to Research and clinical trials. The original article is from PubMed Central.

The study presents preclinical data that an orally delivered biotherapeutic (EPICERTIN) promotes epithelial repair and reduces inflammation in a UC-relevant mouse model — a potential step toward therapies that directly...

If validated, a simple ultrasound-based score could reduce the need for invasive endoscopy to monitor disease activity in children with ulcerative colitis. Noninvasive monitoring is especially valuable in pediatrics.

Fibrosis causes strictures and surgery in many people with Crohn’s disease; a new immune pathway linked to fibrosis could point to future treatments. This study shows that γδ T cells and CD73-mediated adenosine signaling...

This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to...

This study addresses whether removing the appendix changes long-term UC outcomes. People with UC or their clinicians might expect surgery to alter disease course; these real-world data suggest it generally does not for...

This review outlines BEVs as a microbiome-derived, engineered nanotherapy concept that could influence gut barrier repair and immune regulation—areas directly relevant to managing IBD activity and treatment resistance.

Many people with Crohn’s disease have ongoing inflammation despite stable medication. If dietary personalization can reduce inflammation, it could offer a nonpharmacologic add-on to help bridge gaps without immediate...

Researchers and clinicians looking for blood- or tissue-based molecular tests for IBD may find these integrated transcriptomic analyses useful because they identify candidate diagnostic biomarkers and highlight shared...

TL1A-blocking antibodies have shown promising response rates in early trials for both Crohn's disease and ulcerative colitis. Understanding TL1A biology could help match new therapies to the patients most likely to...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from ˜The œLancet. Gastroenterology &...

The analysis suggests that placebo arms in Phase 3 IBD trials are associated with higher rates of serious events, mainly disease exacerbations; this matters because it raises ethical and safety concerns for people with...

If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.

Early, noninvasive biomarkers could help detect ulcerative colitis and related colorectal cancer risk sooner. This study identifies four serum-accessible proteins with promising diagnostic accuracy in the reported...

This review explains mechanisms by which gut inflammation can reprogram bone marrow and innate immunity, a process that may help explain persistent inflammation and risks like colitis-associated cancer. Understanding...

This trial directly informs a common clinical question: whether patients in deep remission can safely stop anti‑TNF therapy. Results show higher relapse risk after withdrawal, but many patients can be successfully...